{"filings":[{"id":3347716,"accession_number":"0001493152-26-046354","cik":1449349,"company_name":"VIVOS INC","ticker":"RDGL","form_type":"8-K","filed_at":"2026-10-08T20:46:11+00:00","items":["1.01","3.02","3.03","5.03","9.01"],"status":"ready","headline":"Vivos director Cadwell buys 250K Series D preferred for $250K; Series C canceled","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Director Carl Cadwell agreed to purchase 250,000 shares of Series D Convertible Preferred at $1.00/share, a $250,000 purchase price paid by wire transfer on October 1, 2026.","Cadwell also exchanged 385,302 Series C Preferred (stated value $385,302) for 385,302 Series D Preferred; the Share Exchange closed October 7, 2026.","After closing, Vivos has 635,302 Series D Preferred outstanding with a conversion price of $0.08 per share, and zero Series C Preferred outstanding.","Vivos filed a Certificate of Elimination of the Series C Convertible Preferred with Delaware on October 8, 2026, approved by the Board.","Series D designation was filed September 28, 2026, covering 1.0 million of the company's 10.0 million authorized preferred shares; shares issued under Section 4(a)(2)/Rule 506(b)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":33584561.75438596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3266959,"accession_number":"0001493152-26-045780","cik":1449349,"company_name":"VIVOS INC","ticker":"RDGL","form_type":"8-K","filed_at":"2026-10-05T21:26:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Vivos designates 1M Series D preferred with $1.00 stated value, $0.08 conversion price and 50 votes per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Certificate of Designations filed with Delaware on Sept 28, 2026 designates 1.0M of the company's 10.0M authorized preferred shares as Series D Convertible Preferred, par value $0.001.","Each Series D share carries a $1.00 stated value and $1.00 liquidation preference, convertible at $0.08 per common share — 12.5 shares per preferred, up to 12.5M common shares.","Series D ranks senior to the common stock and all other junior equity, and votes alongside common at 50 votes for every common share issuable upon conversion.","Conversion is capped at 4.99% beneficial ownership, or 9.99% after 61 days' prior written notice to the company; holders may convert at any time.","The filing discloses no dividend rate, purchase price, or investor identity for the Series D issuance; CEO Michael K. Korenko signed the report dated Oct 5, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":33584561.75438596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137009,"accession_number":"0001493152-25-014694","cik":1449349,"company_name":"VIVOS INC","ticker":"RDGL","form_type":"8-K/A","filed_at":"2025-09-24T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Vivos appoints Brad Allan Weeks as President and David J. Swanberg as COO, effective Sept 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Weeks appointed President; base salary $192,000/yr plus $3,000/month in common stock.","Swanberg appointed COO under consulting agreement; fee $12,000/month plus $3,000/month in common stock.","Weeks previously served as Business Development Manager; Swanberg as Chief Technical Manager since 2017.","Employment and consulting agreements run through Dec 31, 2027 and Dec 31, 2028 respectively."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":33584561.75438596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137011,"accession_number":"0001493152-25-014345","cik":1449349,"company_name":"VIVOS INC","ticker":"RDGL","form_type":"8-K","filed_at":"2025-09-22T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Vivos appoints Brad Allan Weeks as President and David J. Swanberg as COO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brad Allan Weeks appointed President effective Sept 1, 2025, with base salary $192,000/yr plus monthly stock grants.","David J. Swanberg appointed COO via consulting agreement at $12,000/month plus stock grants.","Weeks previously served as Business Development Manager; Swanberg has 35+ years in radiochemical processing and was co-founder of IsoRay.","President term ends Dec 31, 2027; COO term ends Dec 31, 2028; both agreements include confidentiality and non-compete clauses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":33584561.75438596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137010,"accession_number":"0001493152-25-014047","cik":1449349,"company_name":"VIVOS INC","ticker":"RDGL","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Vivos Inc. creates wholly owned India subsidiary for manufacturing and therapies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved creation of Vivos Scientific India LLP on September 17, 2025.","Entity is wholly owned, aims to establish manufacturing center in India.","Objective includes expanding human therapies and commercialization in India.","Will generate additional human trial data to support FDA approval process."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":33584561.75438596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172876,"accession_number":"0001493152-25-005623","cik":1449349,"company_name":"VIVOS INC","ticker":"RDGL","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vivos reports positive initial RadioGel clinical trial results; plans expansion to 50 patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First 5 patients showed safety; Y-90 remained at injection site with no adverse events.","One patient (cancerous node near trachea) showed over 80% reduction in tumor size and metastatic activity.","Lead investigator to request Ethics Committee approval to expand trial from 30 to 50 patients.","New deep-injection CT-guided device targets deeper tumors (lung, pancreatic); initial trial by June 30, expanded by year-end.","Data to be published and shared with FDA to support IDE submission for expanded U.S. indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":33584561.75438596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172875,"accession_number":"0001493152-25-005588","cik":1449349,"company_name":"VIVOS INC","ticker":"RDGL","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["3.02","8.01"],"status":"ready","headline":"Vivos raises $1.5M via 12.5M share sale; also issues warrants for 6.25M shares at $0.15","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 12.5M common shares to an accredited investor for gross proceeds of $1.5M under Regulation A+ offering.","Issued warrants to purchase 6.25M shares at $0.15 per share, expiring June 30, 2028, for $6,250 consideration.","Proceeds from the sale will be used for general working capital purposes.","Shares outstanding after issuance: approximately 453.4 million."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":33584561.75438596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206392,"accession_number":"0001493152-24-025735","cik":1449349,"company_name":"VIVOS INC","ticker":"RDGL","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vivos files IDE amendment with FDA to initiate human trials of Radiogel therapy","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Filed IDE amendment with FDA for Radiogel™ Precision Radionuclide Therapy, addressing 63 prior FDA comments.","Submission includes genotoxicity and retention study reports; builds on FDA Breakthrough Device Designation.","Plans to submit to Mayo Clinic IRB for first-in-human trial targeting solid metastatic tumors in papillary thyroid cancer.","Previous IDE (Q211938/S001) commented by 12 FDA reviewers; company prepared to address further questions promptly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":33584561.75438596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242960,"accession_number":"0001493152-24-011040","cik":1449349,"company_name":"VIVOS INC","ticker":"RDGL","form_type":"8-K","filed_at":"2024-03-25T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Vivos Inc. renews CEO Michael Korenko's employment agreement with $295,500 salary, 20,000 RSUs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Michael Korenko continues as CEO under two-year term effective January 1, 2024.","Annual base salary of $295,500 with 4% annual increase.","Grant of 20,000 restricted stock units vesting in four equal installments over two years.","Eligible for quarterly discretionary bonus of $10,000 based on board-determined performance.","Agreement includes customary confidentiality, non-competition, non-solicitation, and clawback provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":33584561.75438596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260327,"accession_number":"0001493152-23-046266","cik":1449349,"company_name":"VIVOS INC","ticker":"RDGL","form_type":"8-K","filed_at":"2023-12-27T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Vivos raises $520k via 8.13M share sale; completes warrant exchanges and amendments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $520,448 from sale of 8,132,000 shares of common stock at ~$0.064 per share under Regulation A+.","Issued Series C Warrants to purchase 8.13M shares at $0.075, expiring Dec 31, 2027, for $8,132 total consideration.","Exchanged 5,000,000 Series B Warrants for 2,500,000 common shares; amended remaining Series B warrants to $0.075 exercise price and extended to Dec 31, 2027.","Amended 6,400,000 Series B-1 Warrants to reduce exercise price to $0.075 and extend expiration to Dec 31, 2027.","Post-issuance outstanding shares: 386,731,533."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":33584561.75438596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260326,"accession_number":"0001493152-23-036853","cik":1449349,"company_name":"VIVOS INC","ticker":"RDGL","form_type":"8-K","filed_at":"2023-10-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vivos posts quarterly update: patent progress, Y-90 cost cut, new clinics","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed utility patent for chiller; hydrogel patent nationalized in over 10 offices covering 63 countries.","New Y-90 source from Eckert & Ziegler Wilmington MA reduces cost by ~$1,000 per therapy.","Certified three new clinics: Indian Creek Veterinary Hospital (small animal) and two equine clinics.","IDE amendment in preparation addressing 60 FDA comments; VX-2 rabbit study ongoing (12 of 21 treated).","Mayo Clinic protocol submitted for IRB pre-review; full-dress rehearsal planned next quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":33584561.75438596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295607,"accession_number":"0001493152-23-015144","cik":1449349,"company_name":"VIVOS INC","ticker":"RDGL","form_type":"8-K","filed_at":"2023-05-02T23:59:59+00:00","items":["3.02","8.01"],"status":"ready","headline":"Vivos completes $640k Regulation A+ stock offering and issues warrants for up to 10.7M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised $640,000 in gross proceeds from sale of 8,000,000 shares.","Series A-1 warrants: 2,665,000 shares at $0.01 each, expiring Dec 31, 2023, for $10,665.","Series B-1 warrants: 8,000,000 shares at $0.10 each, expiring June 30, 2026.","Post-offering shares outstanding: 370,541,528."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":33584561.75438596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351868,"accession_number":"0001493152-22-018978","cik":1449349,"company_name":"VIVOS INC","ticker":"RDGL","form_type":"8-K","filed_at":"2022-07-11T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Vivos raises $1.2M from 15M share sale and $20K from warrant issuance","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Gross proceeds of $1.2M from 15M shares of common stock sold under Regulation A+ on July 7, 2022.","Issued Series A warrants for 5M shares at $0.01/share expiring Dec 31, 2022, and Series B warrants for 15M shares at $0.08/share expiring June 30, 2025, for $20K total.","Proceeds will be used for general working capital; post-issuance shares outstanding are 352.78 million."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":33584561.75438596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388496,"accession_number":"0001493152-22-002410","cik":1449349,"company_name":"VIVOS INC","ticker":"RDGL","form_type":"8-K","filed_at":"2022-01-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vivos 2021 recap: first equine IsoPet therapy, FDA pre-sub for RadioGel IDE, production improved 3x","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["University of Missouri performed first equine IsoPet therapy; excellent outcome confirmed after monitoring.","Pre-submission meeting with FDA for RadioGel IDE; used rapid breakthrough review; revised IDE to be submitted after biocompatibility tests.","Polymer production time reduced and output increased by factor of three; contaminants reduced below FDA guidelines.","New provisional patent filed covering improved hydrogel, other isotopes, and anti-circumvention techniques.","Capital structure in excellent shape: no toxic debt or derivatives; all SEC filings timely."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":33584561.75438596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}